European Journal of Biotechnology and Bioscience

European Journal of Biotechnology and Bioscience


European Journal of Biotechnology and Bioscience
European Journal of Biotechnology and Bioscience
Vol. 3, Issue 9 (2015)

Infliximab: Biological response modifier, chimeric IgG1 therapeutic recombinant monoclonal antibody


Harit Kasana

Infliximab is a chimeric IgG1κ monoclonal antibody (composed of human constant and murinernvariable regions) specific for human tumor necrosis factor-alpha (TNFα). Infliximab is produced by arnrecombinant cell line cultured by continuous perfusion and is purified by a series of steps that includesrnmeasures to inactivate and remove viruses. The annual global sale of Infliximab was $8 billion in 2013,rnaccording to industry data. This article describes the overview of infliximab including mechanism ofrnaction, indications and development genetics.
Pages : 47-50